Functional characterization of mutations in inherited human cPLA₂ deficiency.
Group IVA cytosolic phospholipase A(2) (cPLA(2)α) catalyzes the first step in the arachidonic acid cascade leading to the synthesis of important lipid mediators, the prostaglandins and leukotrienes. We previously described a patient deficient in cPLA(2)α activity, which was associated with mutations in both alleles encoding the enzyme. In this paper, we describe the biochemical characterization of each of these mutations. Using saturating concentrations of calcium, we showed that the R485H mutant was nearly devoid of any catalytic activity, that the S111P mutation did not affect the enzyme activity, and that the known K651R polymorphism was associated with activity slightly higher than that of the wild type. Using MDCK cells, we showed that translocation to the Golgi in response to serum activation was impaired for the S111P mutant but not for the other mutants. Using immortalized mouse lung fibroblasts lacking endogenous cPLA(2)α activity, we showed that both mutations S111P and R485H/K651R caused a profound defect in the enzyme catalytic activity in response to cell stimulation with serum. Taken together, our results show that the S111P mutation hampers calcium binding and membrane translocation without affecting the catalytic activity, and that the mutation R485H does not affect membrane translocation but blocks catalytic activity that leads to inactivation of the enzyme. Interestingly, our results show that the common K651R polymorphism confers slightly higher activity to the enzyme, suggesting a role of this residue in favoring a catalytically active conformation of cPLA(2)α. Our results define how the mutations negatively influence cPLA(2)α function and explain the inability of the proband to release arachidonic acid for eicosanoid production.
Department of Medicine, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232-6602, United States.
Kathleen A
KA
Reed
Dawn E
DE
Tucker
Ahmed
A
Aloulou
David
D
Adler
Farideh
F
Ghomashchi
Michael H
MH
Gelb
Christina C
CC
Leslie
John A
JA
Oates
Olivier
O
Boutaud
D000818:Animals; D055162:Biocatalysis; D002460:Cell Line; D004285:Dogs; D054513:Group IV Phospholipases A2 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D009154:Mutation; D021381:Protein Transport
D054513:Group IV Phospholipases A2
J Biol Chem. 2004 Feb 13;279(7):6005-16
14623879
Nature. 1997 Dec 11;390(6660):622-5
9403693
Annu Rev Physiol. 1989;51:107-24
2496641
J Biol Chem. 1999 May 21;274(21):14979-87
10329700
Prog Lipid Res. 2006 Nov;45(6):487-510
16814865
Nature. 1997 Dec 11;390(6660):618-22
9403692
J Biol Chem. 1994 Jul 8;269(27):18239-49
8027085
Cell. 1999 Apr 30;97(3):349-60
10319815
Prostaglandins Leukot Essent Fatty Acids. 2004 Apr;70(4):373-6
15041029
J Biol Chem. 2001 Aug 10;276(32):30150-60
11375391
Biochemistry. 1998 Jun 9;37(23):8516-26
9622504
J Biol Chem. 1998 Jan 16;273(3):1596-604
9430701
J Biol Chem. 2002 Aug 16;277(33):29526-36
12039969
J Biol Chem. 2009 Apr 3;284(14):9596-611
19176526
J Biol Chem. 1998 Jan 23;273(4):2184-91
9442060
Biochim Biophys Acta. 1990 Aug 6;1045(3):261-70
2167132
J Clin Invest. 2008 Jun;118(6):2121-31
18451993
J Lipid Mediat Cell Signal. 1995 Oct;12(2-3):83-117
8777586
J Biol Chem. 2002 Jun 28;277(26):23838-46
11956215
J Biol Chem. 2003 Jun 27;278(26):23842-50
12672805
Biochim Biophys Acta. 2000 Oct 31;1488(1-2):40-7
11080675